Battle lines form over tobacco‑21 bill as public‑health groups warn of broad local preemption

Representative Ben Keithley introduced House Bill 2,085 as a measure to apply a consistent state standard to the retail sale of tobacco and alternative nicotine products, citing sections 407.924 through 407.934 as the statutory locus of the change. The sponsor said the bill would set the state retail age at 21 and clarified that the bill’s scope is intended to address retailing and sales practices codified in those sections rather than local zoning.

Several committee members sought clarification about scope and consequences. Members asked whether the bill would prevent a city or county from banning all tobacco retail sales; Keithley said the bill would preempt outright bans on products and would occupy the regulatory field referenced by the cited statutory sections, though it would not impose state zoning rules where state standards do not exist.

Public‑health organizations argued the bill’s preemption language is written broadly and could curtail local licensing and permitting powers that give municipalities enforcement authority. Emily Kalmer of the American Cancer Society Cancer Action Network said the industry has used preemption historically as a tactic to limit local action and expressed concern that the bill’s language could be litigated to block local restrictions on proximity to schools, licensing conditions, or permitting. Jacob Scott, representing several medical associations, testified the measure would harm public health by weakening local regulatory tools.

Opponents repeatedly emphasized that federal law already establishes 21 as the national minimum sale age and said the real effect of the bill is to remove municipal tools — such as licensing, permitting and local penalties — that make enforcement meaningful at the local level. Supporters and the sponsor countered the bill’s intent is limited to the retail sale provisions referenced in state statute and is not meant to bar zoning regulations or other local public‑health measures outside the cited retail sections.

The committee question period included requests that sponsors and opponents work on clarifying language; some members expressed skepticism about preemption while others said a uniform standard could reduce confusion. No committee vote occurred during the hearing; multiple witnesses asked to work with the sponsor on specific drafting concerns.